Incomplete Financial Disclosures: In the Letter to the Editor entitled “Reducing Opioid Abuse and Diversion,” published in the July 27, 2011, issue of JAMA (2011;306:382), the financial disclosures were incomplete. They should have appeared as follows: Dr Fine reported receiving payment for serving on the advisory boards of Archimedes, Covidien, King (Pfizer), Meda, Purdue Pharma, Ameritox, Forest Labs, and Neuroadjuvants; providing medical legal consulting for Cephalon and Janssen; participating in CME activities for King (Pfizer), Endo, Pricara, and OrthoMcNeil; serving on speakers' bureaus for Pricara and OrthoMcNeil; receiving funds for research and writing assistance from Cephalon; being the president of the American Academy of Pain Medicine; being a board member of the American Pain Foundation (a nonprofit foundation that receives support from manufacturers of prescription opioids), being co-chair of the American Pain Society–American Academy of Pain Medicine Opioid Guideline panel, for which he received reimbursement for travel expenses; being chair of the National Initiative on Pain Control through the American Pain Foundation; being a strategic consultant for Capital Caring Hospice; serving as an expert witness for Cephalon; receiving grants from the National Institutes of Health; receiving book royalties from The Hospice Companion; having a 5% ownership in Asante medical education company; and being a board member of the Ossipee Lake Alliance. An accompanying letter appears in this issue of JAMA.
Dr Fishman reported having authored the Federation of State Medical Board book Responsible Opioid Prescribing and receiving no royalties; being president and chair of the board of directors of the American Pain Foundation (a nonprofit foundation that receives support from manufacturers of prescription opioids) for which he receives no compensation but is reimbursed for out-of-pocket expenses for coach airfare and cab fare once per year for a board meeting; and having participated in numerous ACCME-certified continuing medical education activities yearly that are organized by academic health systems and/or medical professional organizations for which he received market rate honoraria, some of which were funded by commercial sources related to opioid prescribing although no funds were accepted directly from any commercial sponsors. An accompanying letter appears in this issue of JAMA.
Incomplete Financial Disclosures in: Reducing Opioid Abuse and Diversion. JAMA. 2011;306(13):1446. doi:10.1001/jama.2011.1399